|
1
|
Garkavtsev I, Demetrick D and Riabowol K:
Cellular localization and chromosome mapping of a novel candidate
tumor suppressor gene (ING1). Cytogenet Cell Genet. 76:176–178.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheung KJ Jr and Li G: The tumor
suppressor ING1: Structure and function. Exp Cell Res. 268:1–6.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garkavtsev I, Grigorian IA, Ossovskaya VS,
et al: The candidate tumour suppressor p33ING1 cooperates with p53
in cell growth control. Nature. 391:295–298. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gunduz M, Ouchida M, Fukushima K, et al:
Genomic structure of the human ING1 gene and tumor-specific
mutations detected in head and neck squamous cell carcinomas.
Cancer Res. 60:3143–3146. 2000.PubMed/NCBI
|
|
5
|
Vieyra D, Toyama T, Hara Y, et al: ING1
isoforms differentially affect apoptosis in a cell age-dependent
manner. Cancer Res. 62:4445–4452. 2002.PubMed/NCBI
|
|
6
|
Kataoka H, Bonnefin P, Vieyra D, et al:
ING1 represses transcription by direct DNA binding and through
effects on p53. Cancer Res. 63:5785–5792. 2003.PubMed/NCBI
|
|
7
|
Ythier D, Larrieu D, Brambilla C, et al:
The new tumor suppressor genes ING: Genomic structure and status in
cancer. Int J Cancer. 123:1483–1490. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jäger D, Stockert E, Scanlan MJ, et al:
Cancer-testis antigens and ING1 tumor suppressor gene product are
breast cancer antigens: Characterization of tissue-specific ING1
transcripts and a homologue gene. Cancer Res. 59:6197–6204.
1999.PubMed/NCBI
|
|
9
|
Soliman MA and Riabowol K: After a decade
of study-ING, a PHD for a versatile family of proteins. Trends
Biochem Sci. 32:509–519. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nouman GS, Angus B, Lunec J, et al:
Comparative assessment expression of the inhibitor of growth 1 gene
(ING1) in normal and neoplastic tissues. Hybrid Hybridomics.
21:1–10. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Toyama T, Iwase H, Watson P, et al:
Suppression of ING1 expression in sporadic breast cancer. Oncogene.
18:5187–5193. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheung KJ Jr, Mitchell D, Lin P and Li G:
The tumor suppressor candidate p33(ING1) mediates repair of
UV-damaged DNA. Cancer Res. 61:4974–4977. 2001.PubMed/NCBI
|
|
13
|
Oki E, Maehara Y, Tokunaga E, Kakeji Y and
Sugimachi K: Reduced expression of p33(ING1) and the relationship
with p53 expression in human gastric cancer. Cancer Lett.
147:157–162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ito K, Kinjo K, Nakazato T, Ikeda Y and
Kizaki M: Expression and sequence analyses of p33(ING1) gene in
myeloid leukemia. Am J Hematol. 69:141–143. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tallen G, Riabowol K and Wolff JE:
Expression of p33ING1 mRNA and chemosensitivity in brain tumor
cells. Anticancer Res. 23:1631–1635. 2003.PubMed/NCBI
|
|
16
|
Garkavtsev I, Kazarov A, Gudkov A and
Riabowol K: Suppression of the novel growth inhibitor p33ING1
promotes neoplastic transformation. Nat Genet. 14:415–420. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shinoura N, Muramatsu Y, Nishimura M,
Yoshida Y, Saito A, Yokoyama T, Furukawa T, Horii A, Hashimoto M,
Asai A, et al: Adenovirus-mediated transfer of p33ING1 with p53
drastically augments apoptosis in gliomas. Cancer Res.
59:5521–5528. 1999.PubMed/NCBI
|
|
18
|
Lv Y, Purbey BK, Huang Y, Li S, Radha G
and Hao Z: Adenovirus-mediated expression of p33(ING1b) induces
apoptosis and inhibits proliferation in gastric adenocarcinoma
cells in vitro. Gastric Cancer. 15:355–362. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morán A, Ortega P, de Juan C,
Fernández-Marcelo T, Frías C, Sánchez-Pernaute A, Torres AJ,
Díaz-Rubio E, Iniesta P and Benito M: Differential colorectal
carcinogenesis: Molecular basis and clinical relevance. World J
Gastrointest Oncol. 2:151–158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Center MM, Jemal A, Smith RA and Ward E:
Worldwide variations in colorectal cancer. CA Cancer J Clin.
59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen LS, Wei JB, Zhou YC, Zhang S, Liang
JL, Cao YF, Tang ZJ, Zhang XL and Gao F: Genetic alterations and
expression of inhibitor of growth 1 in human sporadic colorectal
cancer. World J Gastroenterol. 11:6120–6124. 2005.PubMed/NCBI
|
|
23
|
Rhoads TW, Williams JR, Lopez NI, et al:
Using theoretical protein isotopic distributions to parse
small-mass-difference post-translational modifications via mass
spectrometry. J Am Soc Mass Spectrom. 24:115–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen L, Matsubara N, Yoshino T, Nagasaka
T, Hoshizima N, Shirakawa Y, Naomoto Y, Isozaki H, Riabowol K and
Tanaka N: Genetic alterations of candidate tumor suppressor ING1 in
human esophageal squamous cell cancer. Cancer Res. 61:4345–4349.
2001.PubMed/NCBI
|
|
25
|
Russell M, Berardi P, Gong W and Riabowol
K: Grow-ING, Age-ING and Die-ING: ING proteins link cancer,
senescence and apoptosis. Exp Cell Res. 312:951–961. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nouman GS, Anderson JJ, Mathers ME, et al:
Nuclear to cytoplasmic compartment shift of the p33ING1b tumour
suppressor protein is associated with malignancy in melanocytic
lesions. Histopathology. 40:360–366. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nouman GS, Anderson JJ, Wood KM, et al:
Loss of nuclear expression of the p33(ING1b) inhibitor of growth
protein in childhood acute lymphoblastic leukaemia. J Clin Pathol.
55:596–601. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nouman GS, Anderson JJ, Crosier S, et al:
Downregulation of nuclear expression of the p33(ING1b) inhibitor of
growth protein in invasive carcinoma of the breast. J Clin Pathol.
56:507–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen XY, Zhu TH and Li Y: Advances in the
research on ING gene family. J Mol Med. 2:83–92. 2005.
|
|
30
|
Ohgi T, Masaki T, Nakai S, Morishita A,
Yukimasa S, Nagai M, Miyauchi Y, Funaki T, Kurokohchi K, Watanabe S
and Kuriyama S: Expression of p33(ING1) in hepatocellular
carcinoma: Relationships to tumour differentiation and cyclin E
kinase activity. Scand J Gastroenterol. 37:1440–1448. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shimada H, Liu TL, Ochiai T, et al:
Facilitation of adenoviral wild-type p53-induced apoptotic cell
death by overexpression of p33(ING1) in T.Tn human esophageal
carcinoma cells. Oncogene. 21:1208–1216. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Skowyra D, Zeremski M, Neznanov N, et al:
Differential association of products of alternative transcripts of
the candidate tumor suppressor ING1 with the mSin3/HDAC1
transcriptional corepressor complex. J Biol Chem. 276:8734–8739.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nagashima M, Shiseki M, Miura K, et al:
DNA damage-inducible gene p331NG2 negatively regulates cell
proliferation through acetylation of p53. Proc Natl Acad Sci USA.
98:9671–9676. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsang FC, Po LS, Leung KM, et al: ING1b
decreases cell proliferation through p53-dependent and -independent
mechanisms. FEBS Lett. 553:277–285. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Coles AH, Liang H, Zhu Z, et al: Deletion
of p37Ing1 in mice reveals a p53-independent role for Ing1 in the
suppression of cell proliferation, apoptosis, and tumorigenesis.
Cancer Res. 67:2054–2061. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rochette PJ, Bastien N, Lavoie J, Guérin
SL and Drouin R: SW480, a p53 double-mutant cell line retains
proficiency for some p53 functions. J Mol Biol. 352:44–57. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Haupt S, di Agostino S, Mizrahi I,
Alsheich-Bartok O, Voorhoeve M, Damalas A, Blandino G and Haupt Y:
Promyelocytic leukemia protein is required for gain of function by
mutant p53. Cancer Res. 69:4818–4826. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
D'Anna JA, Valdez JG, Habbersett RC and
Crissman HA: Association of G1/S-phase and late S-phase checkpoints
with regulation of cyclin-dependent kinases in Chinese hamster
ovary cells. Radiat Res. 148:260–271. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li N, Li Q, Cao X, et al: The tumor
suppressor p33ING1b upregulates p16INK4a expression and induces
cellular senescence. FEBS Lett. 585:3106–3112. 2011. View Article : Google Scholar : PubMed/NCBI
|
